Clinical translation
Mayo Clinic is uniquely positioned not only to develop new biotherapies but also to deliver them to the patients who need them through early-stage clinical trials. The studies listed on this page demonstrate the wide range of products that the Center for Biomedical Therapeutics is manufacturing for active clinical trials to help support translation into new treatments and new hope for patients.
| Disease or condition |
Product or technology |
Trial name and link |
Principal investigator |
| Cancer — hematologic |
Chimeric antigen receptor (CAR)-T cell therapy |
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies |
Saad J. Kenderian, M.B., Ch.B. |
| Cancer — hematologic |
CAR-T cell therapy |
Safety and Efficacy of B-cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells in Subjects With Relapsed or Refractory BAFFR-Expressing B-cell Hematologic Malignancies |
Mohamed A. Kharfan Dabaja, M.D., M.B.A. |
| Cancer — liver |
Dendritic cells |
A Study of Intratumoral Injection of Dendritic Cells After High-Dose Conformal External Beam Radiotherapy in Patients With Unresectable Liver Cancer |
Lewis R. Roberts, M.B., Ch.B., Ph.D. |
| Cancer — reproductive |
Dendritic cells |
FrαDcs or Placebo for Patients With Advanced Stage Ovarian Cancer |
Matthew S. Block, M.D., Ph.D.;
Gerardo Colon-Otero, M.D.;
Nina J. Karlin, M.D.
|
| Cancer — reproductive |
Dendritic cells |
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (FRAPPE) |
Matthew S. Block, M.D., Ph.D.;
Gerardo Colon-Otero, M.D.;
Brenda J. Ernst, M.D.
|
| Cancer — reproductive |
Muc1 T cells |
Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian Cancer |
Brenda J. Ernst, M.D. |
| Cancer — solid tumor |
Peptide vaccine |
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study |
Yanyan Lou, M.D., Ph.D. |
| Cardiovascular disease |
Allogeneic adipose MSCs |
A Study To Evaluate Mesenchymal Stem Cells for Reducing Anastomotic Stenosis |
Sam Farres, M.D. |
| Crohn’s disease |
Autologous adipose MSCs plus matrix |
A Study To Analyze AVB-114 To Treat Complex Crohn’s Perianal Fistulas in Subjects with Quiescent Rectal Disease |
Jana G. Al Hashash, M.D., M.S.;
Justin T. Brady, M.D.;
Konstantinos A. Papadakis, M.D.
|
| Epilepsy |
Allogenic adipose MSCs |
Allogenic Adipose-Derived Mesenchymal Stem Cells for Epilepsy During Deep Brain Stimulation Surgery |
Sanjeet S. Grewal, M.D. |
| Joint damage — lumbar |
Allogeneic bone marrow MSCs |
Allogeneic, Culture-Expanded Bone Marrow-Derived Mesenchymal Stem Cells To Treat Painful Lumbar Facet Joint Arthropathies |
Wenchun Qu, M.D., Ph.D. |
| Multiple system atrophy |
Autologous adipose MSCs |
A Study To Evaluate Mesenchymal Stem Cells To Treat Multiple System Atrophy |
Wolfgang Singer, M.D. |
| Transplant — kidney |
Allogeneic adipose MSCs |
Adipose-Derived MSC To Treat Rejection in Kidney Transplant Recipients |
Timucin Taner, M.D., Ph.D. |
| Ulcerative colitis |
Autologous adipose MSCs |
A Study To Evaluate Intra-Arterial Delivery of Mesenchymal Stem Cells for Luminal Ulcerative Colitis |
William A. Faubion Jr., M.D. |